ArticleRegenerative therapy2025
Bone morphogenetic protein-2-derived osteogenic peptide promotes bone regeneration via osteoblastogenesis.
Article in Regenerative therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Screening of a quinonoid compounds library identifies decylubiquinone as an antioxidant and anti-apoptotic agent against glucocorticoid-induced osteoporosis via CD39/CD73/adenosine axis.Bioactive materials · 2026Article
- Synergistic effects of denosumab and BMP-2 on bone regeneration in critical-sized femoral defects in ovariectomized rats.Journal of materials science. Materials in medicine · 2026Article
- Comparative Analysis of the Osteogenic Potential of Long-Term Dry-Stored Deciduous and Fresh Permanent Tooth-Derived Dentin Matrix.Materials (Basel, Switzerland) · 2026Article
- Therapeutic potential of natural products from Traditional Chinese Medicine in the treatment of osteoporosis.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Bone morphogenetic protein (BMP)-2 plays a critical role in stimulating human mesenchymal stromal cells (hMSCs) differentiation, a key process in bone regeneration. However, the clinical application of BMP-2 has been hindered by several adverse effects. This study evaluated the effectiveness of a newly synthesized BMP2-derived osteogenic peptide (OP), which may overcome the limitations of BMP-2 while preserving its osteogenic potential. Methods: OP5, selected from the OP family based on its osteogenic potential, was tested Results: The optimal OP5 concentration of 1 μM supported hMSC viability and exhibited potent osteogenic activity. OP5 significantly activated BMP receptor types IA and II binding and the osteogenic protein kinase A and phosphorylated cAMP response element-binding protein signaling pathway. OP5-induced gene expressions of alkaline phosphatase and osteocalcin peaked on day 4 (early osteogenesis) and were sustained until day 14 (late osteogenesis). Conclusions: OP5, a low-molecular-weight peptide with strong osteogenic potential, may be a viable alternative to BMP-2 for clinical bone regeneration, minimizing BMP2-associated adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.